Genzyme of Cambridge, Massachusetts, faces millions in lost revenue from its top-selling specialty drugs Cerezyme and Fabrazyme as result of a viral contamination at its Allston, Massachusetts plant.

The company remains convinced of the product's merits and—bolstered by the backing of a $1.38 billion deal from Genzyme a year ago—continues to pursue cardiac and other autoimmune indications.

Chesbrough, Henry W., and Clarissa Ceruti. "Genzyme: Engineering the Market for Orphan Drugs." Harvard Business School Case 602-147, March 2002. (Revised May 2002.) ...